Krebs Biochemicals & Industries Ltd. (KREBSBIO): Krebs Biochemicals & Industries Share Price Rises 9.93% Today

Krebs Biochemicals & Industries Ltd. closed in focus at Rs 58.8, up 9.93% today, with a market capitalisation of Rs 115.33 crore in the micro-cap Healthcare space.

Krebs Biochemicals Share Price is in focus after the stock rose 9.93% today to Rs 58.8, taking the company’s market capitalisation to Rs 115.33 crore. In Stock Market Today trade, the move placed Krebs Biochemicals & Industries Ltd. among the notable micro-cap names being watched for a verified same-day price rise. The supplied data confirms the price event clearly: the stock closed above its previous close of Rs 53.49 after a gain of Rs 5.31 in today’s session.

For investors tracking Krebs Biochemicals Share Price Today, the key takeaway is straightforward. The stock was flagged under the PRICE_RISE_THRESHOLD event, and the 9.93% move was enough for it to qualify as a top gainer within its market-cap bucket. The supplied figures confirm what happened in price terms, though they do not establish a company-specific catalyst behind the move. That distinction matters in Krebs Biochemicals Stock News because a strong one-day rise and a confirmed trigger in the screening system are not the same as a verified business announcement.

What also makes this Krebs Biochemicals Share Price update noteworthy is the combination of a sharp day gain and a very small turnover base. The day’s turnover stood at Rs 0 crore, while total traded volume was 6,077 shares across exchanges, including 6,076 shares on NSE and 1 share on BSE. For readers of Univest following Stocks in News, that means price action was strong in percentage terms, but investors should also watch participation, valuation and industry positioning next.

Krebs Biochemicals & Industries Ltd. (KREBSBIO) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 58.8
Previous Close	Rs 53.49
Today's Change	+Rs 5.31 (+9.93%)
Day Open	Rs 58.8
Day High	Rs 58.8
Day Low	Rs 58.8
Current Volume (BSE)	1
BSE Traded Volume	1
NSE Traded Volume	6,076
Combined NSE + BSE Volume	6,077
Turnover	Rs 0 crore
Market Capitalisation	Rs 115.33 crore
Market Cap Category	Micro Cap

Krebs Biochemicals & Industries Ltd. (KREBSBIO) traded at Rs 58.8. versus the previous close of Rs 53.49, a rise of 9.93%. The stock opened at Rs 58.8, reached Rs 58.8, touched Rs 58.8. Reported volume was 1.

Krebs Biochemicals & Industries Ltd. (KREBSBIO) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 115.33 crore
P/E Ratio	-8.99x
P/B Ratio	-0.71x
ROE	0%
ROCE	-40.28%
EPS	Rs -6.54
Dividend Yield	0%

Krebs Biochemicals & Industries Ltd. was valued at a P/E ratio of -8.99x, a P/B ratio of -0.71x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 0% and ROCE of -40.28%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs -6.54, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Krebs Biochemicals Fundamental Analysis shows why today’s price rise should be read with context rather than in isolation. The company’s market capitalisation stands at Rs 115.33 crore, placing it firmly in the micro-cap bracket where percentage moves can stand out quickly. On valuation, the stock is trading at a P/E ratio of -8.99 and a P/B ratio of -0.71. Negative multiples usually reflect losses or negative net worth dynamics in the underlying financial profile rather than a conventional value discount.

The profitability metrics support that interpretation. Return on equity is 0, while ROCE stands at -40.28%. In plain terms, the supplied numbers do not yet show strong capital efficiency. EPS is -6.54, indicating negative earnings attributable to each share on the supplied basis. Dividend yield is 0, which means the current data does not point to a cash payout component in the stock’s present investment profile.

This mix matters in Krebs Biochemicals Stock Analysis because a one-day price rise and a favourable fundamental setup are not the same thing. A stock can rise sharply on a given day and still carry weak profitability readings. Here, the negative P/E, negative P/B and negative ROCE together suggest that investors tracking Krebs Biochemicals Share Price should separate market action from business quality indicators. The rise has made the stock visible in Share Market Today discussions, but the underlying financial ratios remain challenging when judged on profitability and capital returns.

At the same time, the market-cap figure of Rs 115.33 crore shows that the company is not one of the smallest names in its industry set, even though it is below the broader industry average size. That can matter in liquidity, visibility and peer comparison. Univest readers looking at Krebs Biochemicals Financial Results context should therefore focus less on the one-day move alone and more on whether future reported numbers improve profitability metrics such as EPS, ROE and ROCE. That ownership and market-structure context then connects naturally to how the company sits within the Healthcare and Pharmaceuticals & Drugs benchmark.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	-8.99x
Benchmark Median P/E	25.99x
Benchmark Average P/E	81.5x
Benchmark P/E Range	3.3x to 3,493.04x
Company P/B Ratio	-0.71x
Benchmark Median P/B	1.86x
Company ROE	0%
Benchmark Median ROE	10.59%
Company ROCE	-40.28%
Benchmark Median ROCE	12.98%
Company Market Capitalisation	Rs 115.33 crore
Benchmark Median Market Cap	Rs 144.63 crore

Krebs Biochemicals & Industries Ltd. (KREBSBIO) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Krebs Biochemicals & Industries Ltd. (KREBSBIO) has a P/E ratio of -8.99x, which is below the benchmark median of 25.99x, a difference of -134.59%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Krebs Biochemicals & Industries Ltd. (KREBSBIO) has a ROE of 0%, which is below the benchmark median of 10.59%, a difference of -100%. Krebs Biochemicals & Industries Ltd. (KREBSBIO) has a ROCE of -40.28%, which is below the benchmark median of 12.98%, a difference of -410.32%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Krebs Biochemicals Share Price is moving within the Healthcare sector and the Pharmaceuticals & Drugs industry, and the supplied benchmark offers a useful frame for today’s move. The comparison set covers 137 companies in the same industry, which is broad enough to show how the company’s valuation and profitability stand against listed peers rather than against the market in general.

On P/E, Krebs Biochemicals & Industries Ltd. is at -8.99, while the same-industry benchmark median is 25.99 and the average is 81.5 across 104 companies with available P/E data. The industry P/E range runs from 3.3 to 3493.04. That makes Krebs Biochemicals an outlier on the negative side versus the benchmark’s central tendency. On P/B, the company is at -0.71, compared with a median of 1.86 and an average of 2.51 across 136 companies, with an industry range from -16.76 to 16.42.

Profitability comparisons are also weak relative to the benchmark. Company ROE is 0 against an industry median of 10.59 and average of 8.23 across 136 companies. Company ROCE is -40.28 against a median of 12.98 and average of 15.71. On market size, the company’s market capitalisation of Rs 115.33 crore is below the industry median of Rs 144.63 crore and well below the average of Rs 500.48 crore. The wider market-cap range in the benchmark spans from Rs 6.16 crore to Rs 3,060.41 crore.

For Krebs Biochemicals Latest News and sector analysis, the implication is balanced. The stock’s price action is strong on the day, but its supplied valuation and return metrics sit below the benchmark centre on several counts. That does not negate the price rise, but it does mean investors watching Momentum Stocks in Healthcare should judge today’s strength alongside industry-relative financial quality rather than treating price action as a standalone conclusion. Univest sees this as a stock where market movement is clear, while sector-relative fundamentals remain the more cautious part of the picture.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	3,060.41	31.3	0.46	-2.89	-0.26
Hikal Ltd.	HIKAL	2,862.43	0	2.29	15.22	16.15
Kwality Pharmaceuticals Ltd.	KPL	2,652.52	40.87	8.32	28.21	26.35
Beta Drugs Ltd.	BETA	2,623.92	67.31	10.65	18.65	22.17
Panacea Biotec Ltd.	PANACEABIO	2,571.92	0	3.06	0	5.36

Krebs Biochemicals & Industries Ltd. (KREBSBIO) has a P/E ratio of -8.99x compared with the displayed peer median of 31.3x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 0% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at -40.28% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Krebs Biochemicals & Industries Ltd. (KREBSBIO) has a market capitalisation of Rs 115.33 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Krebs Biochemicals Share Price looks very different when compared with the supplied listed peers from the same Pharmaceuticals & Drugs universe. In market-cap terms, the company at Rs 115.33 crore is far smaller than peers such as Dishman Carbogen Amcis Ltd. at Rs 3,060.41 crore, Hikal Ltd. at Rs 2,862.43 crore, Kwality Pharmaceuticals Ltd. at Rs 2,652.52 crore, Beta Drugs Ltd. at Rs 2,623.92 crore and Hester Biosciences Ltd. at Rs 2,072.78 crore. That size gap matters because it often influences liquidity, market attention and how sharply a stock can move in percentage terms.

Valuation and return ratios also show a wide divergence. Krebs Biochemicals carries a P/E of -8.99, while peer P/E values where available include 31.3 for Dishman Carbogen, 40.87 for Kwality Pharmaceuticals, 67.31 for Beta Drugs, 167.74 for Sai Parenteral's, 46.11 for Fredun Pharmaceuticals, 44.1 for NGL Fine-Chem and 15.31 for Hester Biosciences. The company’s negative multiple stands apart from those positive peer readings.

On P/B, Krebs Biochemicals is at -0.71, versus 0.46 for Dishman Carbogen, 2.29 for Hikal, 8.32 for Kwality Pharmaceuticals, 10.65 for Beta Drugs, 3.06 for Panacea Biotec, 1.93 for Solara Active Pharma Sciences, 3.1 for Sai Parenteral's, 6.89 for Fredun Pharmaceuticals, 6.45 for NGL Fine-Chem and 4.58 for Hester Biosciences. Return metrics show the same gap. Krebs Biochemicals has ROE of 0 and ROCE of -40.28, whereas Hikal posts ROE of 15.22 and ROCE of 16.15, Kwality Pharmaceuticals shows 28.21 and 26.35, Beta Drugs shows 18.65 and 22.17, Solara Active Pharma Sciences shows 17.23 and 15.34, and NGL Fine-Chem shows 27.9 and 33.91.

Even Dishman Carbogen, which has a negative ROE of -2.89 and ROCE of -0.26, still shows less stressed capital-return numbers than Krebs Biochemicals on the supplied data. Panacea Biotec’s ROE is 0, equal to Krebs Biochemicals on that line, but its ROCE of 5.36 is still above the subject company. For readers tracking Krebs Biochemicals NSE and Krebs Biochemicals BSE updates, the conclusion from peer comparison is not about recommendation; it is that the stock’s market size and profitability profile are materially weaker than several better-capitalised healthcare peers, even though today’s price rise has put it on the radar.

Why Investors Are Watching Krebs Biochemicals

Krebs Biochemicals Share Price is being watched because today’s move combined a sharp 9.93% gain with a screen-qualified micro-cap event. In a market where Stocks Rising Today often attract immediate attention, the stock has become relevant not only for price action but also for how that action compares with its valuation, profitability and sector standing.

• Verified price action: the stock rose from Rs 53.49 to Rs 58.8, gaining Rs 5.31 or 9.93% in a single session.
• Market-cap context: the company’s market capitalisation is Rs 115.33 crore and it was flagged in the Micro Cap category.
• Trading participation: total volume was 6,077 shares, split between 6,076 on NSE and 1 on BSE, with turnover at Rs 0 crore.
• Fundamental backdrop: P/E is -8.99, P/B is -0.71, EPS is -6.54, ROE is 0 and ROCE is -40.28.
• Sector position: its P/E, ROE and ROCE sit below the same-industry benchmark medians in Pharmaceuticals & Drugs.

The next things to monitor are whether future Krebs Biochemicals Company News provides a business-specific explanation for investor attention and whether financial metrics begin to improve against the Healthcare benchmark. Univest users may also watch whether trading participation broadens from today’s relatively low-value session, because price action supported by deeper volume can offer a clearer view of market interest than a percentage move alone.

About Krebs Biochemicals

Krebs Biochemicals & Industries Ltd. operates in the Healthcare sector and is classified within the Pharmaceuticals & Drugs industry. That places the company in a listed universe where investors usually evaluate businesses on earnings quality, capital efficiency, valuation multiples and relative market scale. In this case, the benchmark comparison covers 137 companies in the same industry, showing that Krebs Biochemicals is part of a crowded and numerically diverse peer group.

From the supplied data, the company’s current listed identity in the market is best understood through its industry placement and market capitalisation of Rs 115.33 crore. Within the Pharmaceuticals & Drugs space, that makes it a smaller listed participant relative to industry leaders in the peer set such as Dishman Carbogen Amcis, Hikal, Kwality Pharmaceuticals and Beta Drugs, all of which have market capitalisations above Rs 2,000 crore.

For readers following Krebs Biochemicals Stock News, this sector positioning matters because stock moves in healthcare names are often judged not only by price action but also by how the company compares with established listed peers on P/E, P/B, ROE and ROCE. The supplied profile shows a micro-cap pharmaceutical stock currently in focus because of today’s price rise, while the broader company context remains tied to the competitive and financially varied Pharmaceuticals & Drugs segment. Univest presents that context so investors can read today’s move as part of a wider industry picture rather than as an isolated headline.

Track Krebs Biochemicals Share Price on Univest

Use Krebs Biochemicals & Industries Ltd. (KREBSBIO) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Users tracking Krebs Biochemicals Share Price on Univest can follow live price moves, day change, 52-week levels when available, valuation ratios, profitability indicators and sector comparisons in one place. For stocks like Krebs Biochemicals & Industries Ltd., where a single-day move can quickly pull attention, it helps to watch both price action and the underlying metrics such as market capitalisation, P/E, P/B, EPS, ROE and ROCE.

Univest also helps readers place Krebs Biochemicals Share Price Today within broader Market Movers activity by combining stock analysis with industry benchmark data, peer positioning and session-level updates from NSE and BSE. That makes it easier to separate a notable one-day price rise from the longer fundamental questions investors may want to monitor next.

Frequently Asked Questions

What is Krebs Biochemicals Share Price Today?

Ans. Krebs Biochemicals Share Price Today is Rs 58.8. The stock rose Rs 5.31 from its previous close of Rs 53.49, translating into a 9.93% gain in the current session and placing it among notable micro-cap gainers.

Why is Krebs Biochemicals rising today?

Ans. The supplied data confirms that Krebs Biochemicals rose 9.93% today and was flagged under the PRICE_RISE_THRESHOLD event in the Micro Cap category. The figures verify the price move, but they do not establish a company-specific catalyst behind it.

What were the day’s open, high and low for Krebs Biochemicals?

Ans. Krebs Biochemicals opened at Rs 58.8 and the day high and day low were also Rs 58.8. That means the supplied session data shows the stock recorded the same price across its available intraday range markers.

How much market capitalisation does Krebs Biochemicals have?

Ans. Krebs Biochemicals has a market capitalisation of Rs 115.33 crore. That places it in the Micro Cap category, which is important because today’s 9.93% share price rise was assessed within that market-cap classification.

What does the trading volume show for Krebs Biochemicals today?

Ans. Total traded volume stood at 6,077 shares today. Of this, 6,076 shares were on NSE and 1 share was on BSE, while reported turnover was Rs 0 crore, indicating a very small-value trading session.

Is Krebs Biochemicals profitable based on the supplied data?

Ans. The supplied financial ratios do not indicate strong profitability. EPS is -6.54, P/E is -8.99, ROE is 0 and ROCE is -40.28, showing that today’s price rise comes alongside weak reported earnings and return metrics.

How does Krebs Biochemicals compare with its industry benchmark?

Ans. Krebs Biochemicals has a P/E of -8.99 versus the same-industry median of 25.99, ROE of 0 versus 10.59, and ROCE of -40.28 versus 12.98. Its market capitalisation of Rs 115.33 crore is also below the median Rs 144.63 crore.

What is the P/B ratio of Krebs Biochemicals?

Ans. Krebs Biochemicals has a P/B ratio of -0.71. In the same Pharmaceuticals & Drugs industry benchmark, the median P/B is 1.86 and the average is 2.51, showing the company sits below the benchmark centre on this metric.

Which sector and industry does Krebs Biochemicals belong to?

Ans. Krebs Biochemicals belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied sector snapshot compares it against 137 companies in the same industry, giving context to its valuation and profitability numbers.

What should investors monitor after today’s Krebs Biochemicals share price rise?

Ans. Investors may track whether future company news explains the move, whether trading participation increases beyond today’s 6,077 shares, and whether financial indicators such as EPS, ROE, ROCE and valuation ratios improve against industry benchmarks.